HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Novel Implant Combats Diastolic Heart Failure

By HospiMedica International staff writers
Posted on 21 Sep 2017
Image: The CORolla device is inserted into a patient\'s heart to treat congestive HF (Photo courtesy of Piotr Flitr/ RHCC).
Image: The CORolla device is inserted into a patient\'s heart to treat congestive HF (Photo courtesy of Piotr Flitr/ RHCC).
A new implantable device can improve cardiac diastolic function by expanding the ventricle wall, helping the heart fill with blood.

The CorAssist Cardiovascular (Haifa, Israel) CORolla device is an elastic implant placed inside the left ventricle in a minimally invasive procedure. The devices operate by harnessing energy during systole (contraction) and releasing it to the left ventricle during diastole (relaxation). The direct internal expansion forces are distributed on the left ventricle wall and septum, thus enhancing the elastic characteristics of the left ventricular wall. CORolla is implanted through a trans apical approach (TAA) or percutaneous approach (PA) in an off-pump procedure.

The CORolla device, which is composed of a series of elastic elements interposed between spiral screws, was developed specifically to treat heart failure with preserved ejection fraction (HFpEF), characterized by diastolic and systolic functional abnormalities that result in exercise intolerance. HFpEF is a complex disease, encompassing a diverse cohort of patients and marked by the presence of multiple etiological mechanisms, but diastolic dysfunction is considered a crucial component of the disease, which affects approximately 50% of patients with chronic heart failure (HF).

“In diastolic heart failure, the heart contracts well, but cannot open enough so that blood can fill. There is no drug or medication for diastolic heart failure,” said Professor Gil Bolotin, MD, of Rambam Health Care Campus (RHCC; Haifa, Israel), who led the first clinical implantation surgery of the device in Robert MacLachlan, a 72-year old Canadian. “In a small operation, through the apex of the heart, we introduce this spring (it’s just a spring), that helps the heart to open and lets the blood go in better than beforehand.”

The Israel Ministry of Health (Jerusalem) has authorized 10 clinical trials at RHCC to test the efficacy of the CORolla implant.

Related Links:
CorAssist Cardiovascular
Rambam Health Care Campus
Israel Ministry of Health

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Radiation Safety Barrier
RayShield Intensi-Barrier

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more